Staging soft tissue sarcoma: Evolution and change

Ca-A Cancer Journal for Clinicians

Volumn 56, Issue 5, 2006, Pages 282-291

  Kotilingam, Dhanasekaran ^a   Lev, Dina Chelouche ^a   Lazar, Alexander J F ^a   Pollock, Raphael E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC IMAGING; HEALTH PROGRAM; HUMAN; MEDICAL SOCIETY; MESENCHYME; METASTASIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR VOLUME;

DISEASE-FREE SURVIVAL; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SARCOMA; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33749524401     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/canjclin.56.5.282     Document Type: Review

References (49)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Brady MS, Gaynor JJ, Brennan MF. Radiation-associated sarcoma of bone and soft tissue. Arch Surg 1992;127:1379-1385.
3. Smith AH, Pearce NE, Fisher DO, et al. Soft tissue sarcoma and exposure to phenoxyherbicides and chlorophenols in New Zealand. J Natl Cancer Inst 1984;73:1111-1117.
4. Beahrs OH, Hensen DE, Hutter RVP, et al (eds). Manual for Staging of Cancer. 4th ed. Philadelphia: JB Lippincott; 1992:120.
5. Fleming ID, Cooper JS, Henson DE, et al (eds). AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven; 1997.
6. Greene FL, Page DL, Fleming ID, et al (eds). AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
7. Eilber FC, Brennan MF, Eilber FR, et al. Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer 2004;101:2270-2275.
8. Demas BE, Heelan RT, Lane J, et al. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol 1988;150:615-620.
9. Somer EJ, Marsden PK, Benatar NA, et al. PET-MR image fusion in soft tissue sarcoma: accuracy, reliability and practicality of interactive point-based and automated mutual information techniques. Eur J Nucl Med Mol Imaging 2003;30:54-62.
10. Vaidya SJ, Payne GS, Leach MO, Pinkerton CR. Potential role of magnetic resonance spectroscopy in assessment of tumour response in childhood cancer. Eur J Cancer 2003;39:728-735.
11. Oya N, Aoki J, Shinozaki T, et al. Preliminary study of proton magnetic resonance spectroscopy in bone and soft tissue tumors: an unassigned signal at 2.0-2.1 ppm may be a possible indicator of malignant neuroectodermal tumor. Radiat Med 2000;8:193-198.
12. Heslin MJ, Lewis JJ, Woodruff JM, Brennan M. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol 1997;4:425-431.
13. Russell WO, Cohen J, Enzinger F, et al. A clinical and pathological staging system for soft tissue sarcomas. Cancer 1977;40:1562-1570.
14. Hajdu SI, Shiu MH, Brennan M. The role of the pathologist in the management of soft tissue sarcomas. World J Surg 1988;12:326-331.
15. Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996;14:869-877.
16. Mandard AM, Petiot JF, Marnay J, et al. Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases. Cancer 1989;63:1437-1451.
17. Ravaud A, Bui NB, Coindre JM, et al. Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials. Br J Cancer 1992;66:961-969.
18. Sears HF, Hopson R, Inouye W, et al. Analysis of staging and management of patients with sarcoma: a ten-year experience. Ann Surg 1980;191:488-493.
19. Saddegh MK, Lindholm J, Lundberg A, et al. Staging of soft-tissue sarcomas. Prognostic analysis of clinical and pathological features. J Bone Joint Surg Br 1992;74:495-500.
20. Ramanathan RC, A'Hern R, Fisher C, Thomas JM. Modified staging system for extremity soft tissue sarcomas. Ann Surg Oncol 1999;6:57-69.
21. Wunder JS, Healey JH, Davis AM, Brennan MF. A comparison of staging systems for localized extremity soft tissue sarcoma. Cancer 2000;88:2721-2730.
22. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980;153:106-120.
23. Coindre JM, Trojani M, Contesso G, et al. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 1986;58:306-309.
24. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers sarcoma group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350-362.
25. Riad S, Griffin AM, Liberman B, et al. Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res 2004;Sep:129-134.
26. Behranwala KA, A'Hern R, Omar AM, Thomas JM. Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol 2004;11:714-719.
27. Blazer DG III, Sabel MS, Sondak VK. Is there a role for sentinel lymph node biopsy in the management of sarcoma? Surg Oncol 2003;12:201-206.
28. Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:739-747.
29. Stojadinovic A, Leung DH, Hoos A, et al. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg 2002;235:424-434.
30. Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 225 patients. Cancer 2003;97:2530-2543.
31. Eilber FC, Rosen G, Nelson SD, et al. Highgrade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg 2003;237:218-226.
32. Packeisen J, Korsching E, Herbst H, et al. Demystified ... tissue microarray technology. Mol Pathol 2003;56:198-204.
33. Hieken TJ, Das Gupta TK. Mutant p53 expression: a marker of diminished survival in well-differentiated soft tissue sarcoma. Clin Cancer Res 1996;2:1391-1395.
34. Poncelet C, Walker F, Madelenat P, et al. Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma. Hum Pathol 2001;32:1190-1196.
35. Karpeh MS, Brennan MF, Cance WG, et al. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer 1995;72:986-991.
36. Hoos A, Stojadinovic A, Mastorides S, et al. High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer 2001;92:869-874.
37. Lopez-Guerrero JA, Navarro S, Noguera R, et al. Mutational analysis of the c-KIT AND PDGFRalpha in a series of molecularly well-characterized synovial sarcomas. Diagn Mol Pathol 2005;14:134-139.
38. Kuhnen C, Herter P, Muller O, et al. Beta-catenin in soft tissue sarcomas: expression is related to proliferative activity in high-grade sarcomas. Mod Pathol 2000;13:1005-1013.
39. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-799.
40. Ventura-Holman T, Hahn H, Subauste JS, Maher JF. The Fem1a gene is downregulated in rhabdomyosarcoma. Tumour Biol 2005;26:294-299.
41. Orlow I, Drobnjak M, Zhang ZF, et al. Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival. J Natl Cancer Inst 1999;91:73-79.
42. Bramwell VH, Tuck AB, Wilson SM, et al. Expression of osteopontin and HGF/Met in adult soft tissue tumors. Cancer Biol Ther 2005;4:1336-1341.
43. Weng WH, Ahlen J, Astrom K, et al. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 2005;11:6198-6204.
44. Kim SH, Lewis JJ, Brennan MF, et al. Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas. Clin Cancer Res 1998;4:2377-2382.
45. Carpentieri DF, Nichols K, Chou PM, et al. The expression of WT1 in the differentiation of rhabdomyosarcoma from other pediatric small round blue cell tumors. Mod Pathol 2002;15:1080-1086.
46. Engellau J, Bendahl PO, Persson A, et al. Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol 2005;36:994-1002.
47. Ahlen J, Wejde J, Brosjo O, et al. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin Cancer Res 2005;11:206-216.
48. Lopes JM, Hannisdal E, Bjerkehagen B, et al. Synovial sarcoma. Evaluation of prognosis with emphasis on the study of DNA ploidy and proliferation (PCNA and Ki-67) markers. Anal Cell Pathol 1998;16:45-62.
49. Fuchs B, Inwards CY, Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res 2004;10:1344-1353.